Equities Analysts Issue Forecasts for ATOS Q1 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities research analysts at HC Wainwright increased their Q1 2025 earnings estimates for Atossa Therapeutics in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their previous forecast of ($0.07). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.

Separately, Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Price Performance

Shares of ATOS stock opened at $0.70 on Friday. The company has a market cap of $89.93 million, a PE ratio of -3.16 and a beta of 1.20. Atossa Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.31. The stock’s 50 day simple moving average is $0.79 and its two-hundred day simple moving average is $1.10.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors have recently made changes to their positions in the company. Gallagher Capital Advisors LLC bought a new position in Atossa Therapeutics during the 4th quarter valued at about $25,000. Millennium Management LLC purchased a new position in shares of Atossa Therapeutics during the fourth quarter valued at approximately $28,000. Intech Investment Management LLC bought a new position in shares of Atossa Therapeutics during the third quarter valued at approximately $29,000. Two Sigma Advisers LP raised its holdings in shares of Atossa Therapeutics by 214.1% in the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock worth $40,000 after buying an additional 28,900 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock worth $68,000 after buying an additional 16,853 shares during the period. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.